A study in the Journal of Nuclear Medicine reported on the efficacy of F-18 FDG PET in predicting non-small cell lung cancer response to concomitant chemoradiotherapy. Researchers performed FDG PET scans on 28 patients before treatment, at the end of the second week of treatment and two weeks and three months after the completion of treatment. "The current study in locally advanced NSCLC patients treated with concomitant chemoradiotherapy indicates that early in treatment F-18 FDG PET can be used to predict outcome," researchers wrote.

Full Story:

Related Summaries